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ABSTRACT  
 Background: The appearance of drug resistant malaria especially first line antimalaria 
drugs and insecticide resistant mosquitoes are the major obstacles for malaria control and 
prevention programs. As a means of facing the challenges of searching for new anti-
malarial agents, the current study focused on evaluation of anti-malarial activity of extract 
of leaves of S.abyssinica.  
Methods: Chloroquine-sensitive rodent malaria parasite, Plasmodium berghei (ANKA 
strain) was used to infect the male Swiss Albino mice( age 6–8 weeks and weight of rages 
from 24-30 g ) in 4-day suppressive and prophylactic model. The crude hydromethanolic 
extract and solvent fractions of leaves of S.abyssinica at100mg, 200, and 400 mg/kg doses 
was administered to a group of five mice. level of parasitaemia, packed cell volume , mean 
survival time, and body weight were determined and the significance of the differences 
between mean values of the five groups and within groups was analysed by one-way 
ANOVA followed by post hoc Tukey‘s ,and  paired samples t test respectively . 
Results:  the hydro methanolic extract and the hexane , chloroform and ethyl acetate 
fractions  at 400mg/kg dose   shown 45.60%  , 42.50%, 55.80% and 51.44% (<0.001) 
significant difference parasite chemo suppressive activities respectively  as compared to 
negative control in chemosupresive model.  In chemoprophylactic models, at 400 doses of 
hydro methanolic extract and the chloroform fraction, suppressed the level of parasitaemia 
significantly (p < 0.001) compared to the vehicle-treated groups, 54.41%, and 57.59% %, 
suppression respectively and  revealed positive effect on mean servival time, PCV, weight 
and temperature drop due to parasite infection in  both models.  
 Conclusions: The results collectively indicate that the plant has a promising 
antiplasmodial activity against Plasmodium berghei, which upholds the earlier with the 
invitro antimalaria test results and traditional claims.  
 
Key words: antimalarial leaves of Stephania abyssinica, Plasmodium berghei, hearbal 
medicine  
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1. INTRODUCTION 
1.1. Epidemiology of Malaria 
Malaria remains one of the most deadly infectious diseases affecting the world particularly those 
living in tropical areas of the world. All segments of the population especially the most 
vulnerable groups; children under the age of five years, pregnant women, people in emergency 
situations and immunocompromized patients have been severely affected by malaria (1) 
Malaria is a serious global public health problem that is responsible for million cases of acute 
illness and disease in each year. According to WHO report, by 2015, it was estimated that 214 
million malaria cases, and 438 000 deaths due to malaria infection (1). Most cases in 2015 was 
estimated to occur in the African Region (88%), followed by South-East Asia Region (10%) and 
the  Eastern Mediterranean Region (2%). Similarly, it was   estimated that, in 2015, most deaths 
(90%) was happened in the African Region, followed by the South-East Asia Region (7%) and 
the Eastern Mediterranean Region (2%) (1,2).  Globally, 306 000-malaria deaths in children aged 
less than 5 years was estimated in 2015.  Notably, malaria remains a major killer of children, 
particularly in sub-Saharan Africa(1).  
 
In Ethiopia, 2, 118, 815 cases and 213 deaths were estimated in 2013 according to WHO report 
by 2015. Major plasmodium species are Plasmodium falciparum (59%), Plasmodium vivax 
(41%) ,and  Major anopheles species are anopheles arabiensis, anopheles pharoensis, 
anopheles. funestus,  and anopheles nili(1).In Ethiopia, over 50 million people are at risk. 
Malaria accounts for  proximity to breeding sites(2). Malaria transmission exhibits a seasonal 
and unstable pattern, with transmission varying with altitude and rainfall. Currently, areas less 
than 2,000 meters of altitude are considered malarious. In general, terms, 75% of the landmass of 
Ethiopia is considered at risk of malaria, which corresponds to areas below 2000m. The western, 
central and eastern highlands, as well as the highland-fringe areas along the Rift Valley are 
especially vulnerable to epidemics altitude(1, 3). The burden of malaria has been increasing due 
to a combination of large population movements, increasing large-scale epidemics, mixed 
infections of P. vivax and P. falciparum, increasing parasite resistance to malaria drugs, vector 
resistance to insecticides, low coverage of malaria prevention services, and general poverty. 
Outpatient consultations, inpatient admissions and all in-patient deaths have risen by 21-23% 
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over the last five years. Overall, malaria accounts about 17% of outpatient consultations, 15% of 
admissions and 29% of in-patient deaths(4). 
1.2. Etiology and Life Cycle of Plasmodium 
Malaria is an infectious disease caused by the parasite plasmodia. There are five identified 
species of the parasite causing human malaria, namely, P. vivax, P. falciparum, .ovale, P. 
malariae and P. knowlesi(primarily a pathogen of monkeys)are human malaria species that are 
spread from one person to another by female mosquitoes of the genus Anopheles. Malaria, due to 
Plasmodium falciparum is the most dangerous and prominent of the malaria parasites. It causes 
‗malignant‘ or cerebral malaria that can quickly progress to unconsciousness and death.  (1, 5) 
In P falciparum and P malariae infection, only one cycle of liver cell invasion and 
multiplication occurs, and liver infection ceases spontaneously in less than 4 weeks. Thus, 
treatment that eliminates erythrocytic parasites will cure these infections. In P vivax and P ovale 
infections, a dormant hepatic stage, the hypnozoite, is not eradicated by most drugs, and 
subsequent relapses can therefore occur after therapy directed against erythrocytic parasites. 
Eradication of both erythrocytic and hepatic parasites is required to cure these infections. The 
malaria parasite exhibits complex life cycle involving an Anophelesmosquito and a vertebrate 
host (6, 7).  
 
Figure 1: The life cycle of Plasmodium falciparum(9) 
The infection of a human with P. falciparum commences when a female Anopheles mosquito 
takes a blood meal and injects infective sporozoites into the peripheral circulation then they are 
3 
 
carried by the circulatory system to the liver where they undergo asexual amplification, 
producing infective merozoites.  These are released by the hepatocyte into the blood circulation, 
where they recognize and invade RBCs. The merozoites develop into early trophozoites known 
as ―ring stages‖. These trophozoites further develop into schizonts, which divide into merozoites. 
These are released from the RBCs in order to undergo a new replication cycle (7, 8). Some of the 
trophozoites differentiate into female and male gametocytes. Ingestion of the mature 
gametocytes by the blood-feeding mosquito induces the production of gametes in the mosquito 
midgut(9). The motile flagellated microgametes fertilize the macrogametes to form a zygote. 
Then the zygote develops into an invasive ookinete, which penetrates the gut epithelium and 
develops into an oocyst. Asexual replication within the oocyst results in the production of 
approximately 10,000 sporozoites, migrate to the salivary glands; here they mature and wait until 
the mosquito bites a new host, thus spreading malaria (6-9). 
1.3. Pathophysiology of Malaria 
Malaria presents as an acute febrile illness symptoms such as, chills and rigors, followed by 
fever spikes up to 40° C, then profuse sweating.   There may alternate with relatively 
asymptomatic periods, and are associated with extremely high levels of tumor necrosis factor-α 
(TNF-α), which may originate from macrophages stimulated by glycosyl phosphatidylinositol 
moieties or other substances released on schizont rupture. P. falciparum malaria is much more 
acute and severe than malaria caused by other Plasmodiumspecies(7,8) . Almost all deaths 
directly attributable to malaria are caused by severe manifestations of P. falciparum infection, 
including cerebral malaria, severe anemia, respiratory failure, renal failure, and severe malaria of 
pregnancy. Important contributory factors include metabolic acidosis, hypoglycemia, and 
superimposed bacterial infections (10). An important features of the pathogenesis of P. 
falciparumis its ability to sequester in the deep venous microvasculature. It involves a number of 
processes including cytoadherence, resetting, reduced red cell deformability, and the collection 
of infected erythrocytes within the proteoglycan matrix of placental spaces. P. falciparum-
sinfected erythrocytes sequester throughout the human body .Attachment points to endothelium 
with knobs, on the surface of infected erythrocytes where variant cytoadherence proteins 
(PfEMP-1 ;) are anchored. (7, 8, 10). Red blood cells with mature trophozoites stick to the 
vascular walls of small blood veins. This causes a blockage of blood flow. Cerebral malaria 
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occurs when the blockage is in a vein of the brain. This complication has about a 20% mortality 
rate(11,12) . 
1.4. Management of Malaria 
1.4.1. Enviromental Management and Vector Control 
To ensure the prevention and control of malaria, it is important that all temporary or permanent 
breeding sites with water are identified and eliminated. This malaria control strategy is effective 
only when mosquitoes are interrupted from breeding and/or their population is substantially 
decreased. This can be achieved in areas where only a limited number of fully identified 
breeding sites exist(11). 
Mosquito breeding sites malaria can be prevented and controlled by  clearing bodies of water by 
filling  and leveling burrows and pits, and removing undesirable materials that contain water; in 
dry seasons, intermittent rivers and streams that form stream beds, pools and side water pockets 
can be filled, drained or connected to the main course of water(1, 11). 
Larvicides: they can be used to apply on collected water. The most common water-soluble 
chemical used to kill mosquito larvae in Ethiopia is temephos, which is safe for humans when 
used in the recommended dosage, therefore, can be applied to drinking water. However, 
considering its high cost, and the need for repeated applications, spray equipment and human 
resources, temephos should be applied only for small breeding sites, and only if other control 
measures are inapplicable (e.g. in towns, lowlands and agriculture-development areas with 
irrigation systems (3, 11) 
Indoor residual spraying (IRS): Indoor residual spraying (IRS) is the application of long-
acting chemical insecticides on the walls and roofs of all houses and domestic animal shelters in 
a given area, in order to kill adult vector mosquitoes that land and rest on these surfaces. IRS is 
one of the primary vector control interventions for reducing and interrupting malaria 
transmission, and one of the most effective methods for obtaining rapid large-scale impact on 
both vector populations and malaria morbidity/mortality. The primary effects of IRS towards 
curtailing malaria transmission are:  reducing the life span of vector mosquitoes so that they can 
no longer transmit malaria parasites from one person to another; and reducing the density of 
vector mosquitoes(3, 11). 
5 
 
Insecticide treated nets; Insecticide treated nets (ITNs) have been shown to reduce the contact 
between the host and vector leading to significant reduction of malaria transmission. Currently, 
only pyrethroid insecticides have been approved for use on ITNs. These insecticides have very 
low mammalian toxicity but are highly toxic to insects and have a rapid knock-down effect, even 
at low doses. Pyrethroids have a high residual effect, they do not rapidly breakdown unless 
washed or exposed to sunlight (13). 
1.4.2. Insecticide Resistances and mechanisms:  
There are different class of insecticides :organochlorines, organophospahtes , carbamates 
,pyrethroids and etc.(1).Sodium channels modification and acetylcholinesterasemutuation  are 
mechanism of resistance for insectcides(12) as indicated below paragraphs. 
Sodium Channels modification  :Pyrethroids and DDT deliver their toxic, insecticidal effects 
primarily by binding to the sodium channel, altering its gating properties, and keeping it open for 
an unusually long time. Modifications in the sodium channel structure, in the form of either point 
mutations or substitutions resulting from single nucleotide polymorphisms, lead to insensitivity 
to DDT and pyrethroids in the sodium channels of the nervous system via a reduction in or an 
elimination of the binding affinity of the insecticides to proteins (6,13). 
Acetylcholinesterase mutuation :AChE1 and AChE2,  encoded by the ace-1 and ace-2 genes, 
respectively, have been identified in different species of mosquitoes, but only AChE1 has been 
implicated in mosquito resistance to organophosphate and carbamate insecticides (12). 
1.4.3. Drug therapy of Malaria 
Important attributes for the successful implementation of antimalarial drugs are good tolerability 
and safety (especially in young children), affordability, availability in endemic countries and 
short course regimens. Primarily to decrease the emergence of drug resistant parasites, almost all 
antimalarials are now to be administered as part of a combination therapy, with each drug 
targeting distinct mechanisms within the parasite (15).  
Quinine, an aryl-amino alcohol, is one of the oldest antimalarial agents and has been used by the 
native population of Peru for centuries in the form of pulverized bark of the cinchona tree to treat 
fevers and chills; the active alkaloid from the bark was isolated and named quinine. Quinine is 
an erythrocytic schizonticide; now used to treat severe cases of malaria and, as a second line 
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treatment, in combination with antibiotics to treat resistant malaria. Quinine has been 
demonstrated to accumulate in the parasite‘s digestive vacuole (DV) and can inhibit the 
detoxification of heme, an essential process within the parasite. The major adverse effect of 
quinine is cinchonism a syndrome causing nausea, vomiting,tinnitus, and vertigo (13,15) 
 
Piperaquine; it is bis-4-aminoquinoline it possesses an extended half-life of approximately 
5weeks. Due to structure similarities with chloroquine, it has been postulated that piperaquine 
has asimilar mode of action to chloroquine and used for chemophylaxis(13). 
 
Primaquine is an 8-aminoquinoline that eradicates primary exoerythrocytic forms of P. 
falciparum and P. vivax and the secondary exoerythrocytic forms of recurring malarias (P. vivax 
and P. ovale). Primaquine is also gametocidal against human malaria species. It is used clinically 
for standard therapy and terminal prophylaxis. Primaquine has a low incidence of adverse 
effects, except for drug-induced hemolytic anemia in patients with genetically low levels of 
glucose-6-phosphate dehydrogenase
.
(14).  
 
Chloroquine is a 4-aminoquinoline that was introduced in the late 1940s and used on a massive 
scale for malaria treatment and prevention. Its efficacy, affordability and safety, even during 
pregnancy, made it the gold standard treatment of malaria for many years. Chloroquine has one 
of the longest half-lives among antimalarials, which provides a chemoprophylactic effect during 
the drug elimination phase. Chloroquine‘s mechanism of action has been an intense area of 
research for decades and evidence supports that the principal target is the heme detoxification 
pathway in the digestion vacule(DV), where the parasite degrades erythrocytic hemoglobin and 
polymerizes the liberated toxic heme monomers to inert biocrystals of hemozoin(13,14,15). 
 
Mefloquine: it is a synthetic 4-quinoline methanol.  Its exact mechanism of action remains to be 
determined, but like quinine, it can apparently damage the parasite's membrane. It has a long 
half-life (17 days) because of its concentration in various tissues and its continuous circulation 
through the enterohepatic and enterogastric systems (11). The combination of artesunate plus 
mefloquine showed excellent antimalarial efficacy in regions of Southeast Asia with some 
resistance to mefloquine, and this regimen is now one of the combination therapies 
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recommended by the WHO for the treatment of uncomplicated falciparum malaria and 
mefloquine is effective in prophylaxis against most strains of P falciparum and probably all other 
human malarial species (11, 14, 16). 
 
Atovaquone is a lipophilic hydroxynaphthoquinone analog structurally related to ubiquinol (an 
important coenzyme in the electron transport chain within the mitochondria). Molecular 
evidence exists that atovaquone specificallytargets the cytochrome bc1 complex, located in the 
innermitochondrial membrane, thereby inhibiting the respiratory chain (13). In P.falciparum, the 
respiratory chain is required for the regeneration of ubiquinone, the electron acceptor for 
dihydroorotate dehydrogenase, which is an essential enzyme for pyrimidine biosynthesis. 
Atovaquone is  currently used in combination with proguanil (Malarone), mainly as a 
prophylactic(13,16). 
 
Artemisinin: it is derived from the qinghaosu plant, which has been used in Chinese medicine 
for more than two millennia in the treatment of fevers and malaria. Artemisinin (or one of its 
derivatives) is available for the treatment of severe, multidrug-resistant P. falciparum malaria. Its 
antimalarial action involves the production of free radicals within the plasmodium food vacuole, 
following cleavage of the drug's endoperoxide bridge by heme iron in parasitized erythrocytes. It 
is also believed to covalently bind to and damage specific malarial proteins(14,17).  Artemisinin 
is insoluble and can only be used orally. Derivatives of artemisinin have been synthesized to 
increase solubility and improve antimalarial efficacy. The most important of these analogs are 
artesunate (water-soluble; useful for oral, intravenous, intramuscular, and rectal a dministration), 
artemether (lipid-soluble; useful for oral, intramuscular, and rectal administration), and 
dihydroartemisinin (water-soluble; useful for oral administration)(16).  
 
Lumefantrine, an aryl alcohol related to halofantrine, is available only as a fixed-dose 
combination with artemether (Coartem), which is now the first-line therapy for uncomplicated 
falciparum malaria in many countries. Coartem should be administered with fatty food to 
maximize antimalarial efficacy (5, 13). 
 
The antifolate drugs used for malaria therapy are the sulfa drugs sulfadoxine and dapsone that 
inhibit the dihydropteroate synthetase enzyme (PfDHPS), and pyrimethamine and proguanil, 
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which inhibit the dihydrofolatereductase (PfDHFR) activity .The drug combination sulfadoxine–
pyrimethamine (Fansidar); was a highly effective, cheap, well-tolerated drug combination with 
good compliance rates due to being administered in a single dose.  It is used for radical cure and 
causal prophylaxis in malaria control(13, 16). 
 
Tetracyclines and doxycycline; they are active against erythrocytic schizonts of all human 
malaria parasites. They are not active against liver stages. Doxycycline is used in the treatment 
of falciparum malaria in conjunction with quinine, allowing a shorter and better-tolerated course 
of that drug.  Doxycycline has also become a standard chemoprophylactic drug, espescially for 
use in areas of Southeast Asia with high rates of resistance to other antimalarials, including 
mefloquine(5, 16).  
1.4.4. Drug Resistant Malaria 
Drug resistance is the degree to which a disease or disease causing organism remains unaffected 
by a drug which was previously able to eliminate.The efficacy of many antimalarial drugs is 
limited by drug resistance, and recent evidence suggests that parasites are becoming resistant to 
the newest agents. These make the obstacle for achievement of effective for the treatment and 
control of malaria (9, 17-19). 
Chloroquine and Quinine: generally, resistance depends on the chemical class of the antimalarial 
and its mode of action. Resistance to 4-aminoquinolines, Quinine and highly hydrophobic aryl 
aminoalcohols, arises from mutations of genes encoding vacuolar trans-membrane proteins 
which regulate the influx/efflux of the drug at the target and chloroquine resistance in P. 
falciparumis primarily attributable to single nucleotide polymorphisms in pfcrt(CQ resistance 
transporter). Mutations in P. falciparummultidrug resistance 1 (PfMDR1), the gene encoding the 
P. falciparum Pglycoprotein homologue-1, seem to be the main cause of resistance to mefloquine 
but are also implicated in CQ resistance(9, 17, 18). 
Atovaquone;   it specifically inhibits cytochrome bc1 (cytbc1) complex, an important in the 
electron transport system. The mitochondrial electron transport system in P. falciparum is tasked 
with the purpose of regenerating ubiquinone, which in turn serves as an electron acceptor for 
parasitic dihydroorotate dehydrogenase, an enzyme responsible for pyrimidine biosynthesis in 
the parasite. The mechanism of resistance involves a point mutation of cytb gene.(9, 17, 18). 
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Anti-folates: resistance to antifolates is common worldwide and apparently depends on a 
stepwise accumulation of single point mutations of genes pfdhps and pfdhpscoding the drug 
targets, dihydropteroate synthase and dihydrofolatereductase, respectively (9, 17, 18). 
 
Mefloquine:  Resistance to mefloquine has been primarily attributed to amplification in Pfmdr-1 
gene  that encodes for an energy dependent p-glycoprotein pump This p-glycoprotein located on 
the digestion vacuoles (DV) is responsible for extruding out anti-malarials(9, 17, 18).  
Artemisinin and its derivatives: PfATP6 is the only SERCA-type (Sarcoplasma endoplasmic 
reticulum calcium channel) Ca21-ATPase present in the malaria parasite. Inhibition of this 
enzyme subsequently inhibits the action of artemisinin. There is no established mechanism 
behind the development of artemisinin resistance. However, ongoing research has identified 
mutations in the genes encoding for PfATP6 and amplification in the Pfmdr-1(9,17,18). 
Thus, there is an urgent need for increased efforts in anti-malarial drug discovery especially in 
Africa. In recent times, natural products of plant sources have been the center of focus as the 
main source of new, safer and more effective bioactive compounds with medicinal properties. 
1.4.5. Malaria Vaccine 
Candidate vaccine antigens from the pre-erythrocytic stages have been one of the targets of 
antibodies that prevent sporozoite invasion of hepatocytes or the targets of cellular immune 
responses that kill infected hepatocytes. A completely effective pre-erythrocytic vaccine would 
inactivate the parasite before it left the liver, leading to sterile immunity and prevention of 
disease. This goal is to decrease the incidence of new infections, and decrease the number of 
merozoites exiting the liver, by decreasing the number of sporozoites entering the liver or killing 
parasites within hepatocytes, leading to clinical benefits analogous to the direct effects of 
insecticide treated bed nets. Clinical development of RTS,S/AS01E has been reviewed 
extensively . This is by far the most advanced candidate malaria vaccine, is the only one in Phase 
3 evaluation. RTS,S/AS01E has demonstrated 26-51% efficacy(95% confident interval ) in 
reducing the rate of all episodes of malaria (20, 21). However, scientists have employed their 
unlimited efforts to dig out antimalaria vaccine, still there is no licensed finished product found, 
yet. 
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1.5. Traditional Medicine in Malaria Treatment 
In the early development of modern medicine, biologically active compounds from plants have 
played a vital role in providing medicines to combat diseases. Plant-derived medicines continue 
to occupy an important niche in the treatment of diseases worldwide(22). Medicinal plants are 
important sources of traditional medicines for millions of people and additional inputs to modern 
medicine in terms of exploring and producing new drugs. Medicinal plants are useful for curing 
of human diseases because of the presence of photochemical constituents. cinchona tree was 
used to treat malaria as early as the 1600‘s century in South America until it was developed to 
quinine and artemisinin derivatives were isolated from  leaf of Artemisia annuasince this plant 
has been used as a traditional medicine in China for treatment of malaria(23, 24).  
Ethiopian plants have shown remarkably effective medicinal values for many human and 
livestock ailments according to  research findings which have been conducted  on the south, 
southwest, central, north and northwestern parts of Ethiopia(25,26, 27). 
 Having potential rich, medicinal plants, in Ethiopia, are crucial for   pharmacological 
investigation of medicinal properties of the plants (24, 28). Acceptance of traditional medicine 
and limited access to modern healthcare facilities could be considered as the main factors for the 
continuation of the practice (23). 
1.6. Traditional Claimed Antimalarial Plants in Ethiopia 
Peoples in Ethiopia have knowledge and they have been practicing antimalarial plants for 
treatment and prevention.  Plants such as, leaf  of Artemsia afra (Asteraceae) ,seeds of Pavetta 
abyssinica ( Rubiaceaefugi) (29) ,Allium cepa (30), carica papaya (26), shoot apexof Croton 
macrostachyus(Euphorbiaceae),  root of Phytolacca dodecandra (Phytolaccaceae) ,latex  of 
Euphorbiaceae abussinica , apex of  jestica schimperiana (Weesacanthaceae) ,  roots and leaves  
of  Vernonia amygdalina (Asteraceae ) (31). lopididiumsativum ( Brassicaceae) (32), Allium 
sativium  (Alliacea) (33),leaves  of Clematis simensis  (Rananculaceae)  , both stem and root  of 
Phoenix reclinata (34) have been used for management of malaria traditionally in different 
places Ethiopia. 
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1.7. Plants with Promising Invivo Antimalaria Activity 
Leaves of Otostegia integrifolia exhibited  on hydroalcoholic  extractand solvent fractions 
significant antimalarial activity(35).  Similarly, a study on the leaves of Vernonia amygdalina 
against P.berghei   exhibited suppressive effect both of hydro alcoholic extract and chloroform 
fraction. In the same manner ,the antimalarial activity of the hydromethanolic leaf extract of 
Campurin aaurea  was reported in a 4-day suppressive test in P. berghei-infected mouse model 
(36). The crude aqueous extract, crude hydro methanolic extract,   n-hexane fraction of crude 
hydro methanolic extract, chloroform fraction of crude hydromethanolic extract and aqueous 
fraction of crude hydro methanolic extract of the leaf of Strychnos mitis revealed positive 
effect(37). A 80% methanol extract of the stem bark of Syzygium guineense  also showed 
antimalaril activity  significantly(38). 
1.8. Experimental Plant (Stephania abyssinica) 
Stephania abyssinica,a vernacular name, ‟ye ayit hareg‟ or ,‟Este eyesus‟ (Amharic), is a 
climbing shrub within the family Menispermaceae and genus Stephania .It is found widely 
distributed in tropical Africa, including Ethiopia. Its natural habitat includes grassland, 
abandoned fields and roadsides, at elevations up to 3500 m. The members of genus Stephania are 
slender, climbers with peltate and membranous leaves. The arrangements of flowers are in 
umbelliform cymes, which arise from axils or from old leafless stems.  S.abyssinica is a liana 
wood at the base, 2-3 m hight.  The leaves are peltate, broadly ovate, round base and obtuse or 
acute base. Flowers are cream or reddish. Fruits are yellow or pinkish green round and 5-8 mm 
in diameter. Its flowering seasons ranges from spring till early autumn (36, 39,40). 
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Figure 2: photograph of leaf Stephania abyssinica(by Mekuanent Zemene,May 23, 2017) 
 
Traditionally,  leaves of S.abyssinica has been used for treatment of different ailments such as 
the menstrual disorders and child birth problems in Abeokuta south local government area of 
Ogun state in Nigeria (41).  Root has been used to treat malaria and internal parasites throughout 
eastern Africa as well as in Uganda the leaves is believed to distract hunting dogs if they eat the 
leaves, and disorientate hunters if they touch the plant (40).  
The investigation focused on Stephania abyssinica which was identified during a survey of 
traditional anti-malarial plants from southern Nyanza, Kenya (42) and where its aqueous root 
extract has been used for malaria therapy throughout eastern Africa (43) 
In Ethiopia, it is used in Ethiopia as a remedy, including anthrax, stomach problems, 
miscarriage, rabies, syphilis and external tumor/swelling. The dried leaves of S.abyssinica has 
been used for treatment of rabies by Sheko ethnic groups (45). Drinking juice of leaves and 
stems   are used for headache and stomachache in Zegie people , in northern Ethiopia (46);  
infused leaves  is used for anthrax( kurba) and abdominal crump in Gondar town (25) ,  fresh 
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leaf for stomach ache and  rabies in Mecha woreda in west Gojam (32); Southern Ethiopia  leave 
are used for  dermal burn (29) . 
For treatment of tumor, the root of the plant is crushed, squeezed and then spread on affected 
part of the body. In confirmation of the antitumor activity reported, stephanine and stephavanine 
isolated from S. abyssinica have been shown to exhibit antineoplastic activity (44). Root 
decoction of the plant has been also used to treat jaundice,  rabies and ascariasis in Bahirdar 
zuria woreda, anthrax (47) and  as an aphrodisiac (46). Fresh or dried root powder has been used 
for leg ache, arthritis, rheumatism and the whole part of the plant used to treat common cold in 
Wayu Tuka District, East Welega Zone (27). Roots are used for pneumonia, around Fiche 
District, Central Ethiopia   legache. arthirits, rheumatim fresh or poweder root(32). 
Medicinal activities of S.abyssinica also were tested from body parts.  On invitro test, 
antioxidant Activity(roots and rhizomes) was showed (48).  It was also evaluated  and showed as  
the antidiarrheal and antispasmodic activities of the aqueous and methanol extract of the root and 
leaf of S. abyssinica(43).  The 80% methanol leaf extract of S. abyssinica  showed analgesic and 
anti-inlammatory activity on mice(49). 
The solvent fraction S. abyssinica Walp leaves showed antimalarial activity in vitro test against 
chloroquine sensitive and resistant laboratory adapted strains of P. falciparum (36), and aqueous 
extract hepatoprotective effects (48).   It was also reported that it showed strong invitro anti-
plasmodial activity  leaf  of  S.abyssinica (50, 51),however, still  there is no invivo antimalaria 
activities were not evaluated in both crude and  solvent fractions on leaf of S.abyssinica . 
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1.9. Justification of the study 
Malaria continues to be a problem worldwide. Plasmodium will continue to develop resistance 
against antimalarial pharmaceuticals. The parasite develops resistance much faster than the rate 
of new pharmaceuticals is being developed. Currently there is a paucity of promising novel 
antimalarial drugs under development and a loss of the artemisinins to resistance would be a 
disaster for international malaria control(1). Due to  cost ,  side effects  and contra indication  of  
conventional  antimalarial drugs(14), absence of  vaccine(20,21) for  malaria is also still 
challenges for malaria  to combat it.  As a result, searching for new safe, effective, and 
accessible plant originated antimalarial drugs is still in homework for scientists.  
Medicinal plants remain the focus by scientists and researcher as a noble source of lead 
compound in the search and development of new antimalarial agents. Screening of plants for 
antimalarial activity is of paramount importance to the effort made to develop new drugs. Plants 
which were clamed as tradicional medicine, they have been   the source of antimalarial  drugs 
such as quinine and artemisinin (23,24).  
 
The Leaf of S.abyssinica has been traditionally claimed for malaria treatment and strong 
antimalarial activity was also showed  by invitro antimalarial screening(42,50) Therefore, this 
study  was aimed at the evaluation of the claimed traditional use and reported in vitro 
antimalarial activity of the plant material in animal models.  
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2. OBJECTIVE 
2.1. General objective: 
 To evaluate the antimalarial activity of 80% hydromethanolic crude extracts and solvent 
fractions  of leaves of S.abyssinica  against P.berghei  infected mice 
2.2. Specific objectives: 
 To perform preliminary phytochemical screening   of  hydromethanolic crude extracts and 
solvent fractions of the leaves of S.abyssinia. 
 To evaluate chemosupressive activities hydromethanolic crude extracts of leaves of 
S.abyssinica against P.berghei infected mice. 
 To evaluate chemosupressive activities of n-hexane, chloroform and ethyl acetate  fractions 
of leaves of  S.abyssinica   against P.berghei  infected mice  
 To evaluate the effect of the hydromethanolic crude extracts and solvent fractions on mean 
survival time, packed cell volume ,body temperature and body weight of P. berghei infected 
mice 
 To evaluate chemoprophylactic activity of hydromethanolic crude extracts and the most 
active chemo suppressive solvent fraction of the leaves of S.abyssinica. 
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3. MATERIALS AND METHODS 
3.1. MATERIALS 
3.1.1. Equipments, chemicals, reagents and drugs 
Trisodium citrate(Alpha chem.,India), Tween 80 (Avishkar Lab Tech Chemicals, 
India).,Absolute methanol(RANKEM , India ) , Absolute ethanol((Lobachemie ,India ) 
,Chloroquine 250 mg phosphate tablet( Addis pharmaceutical factory, Ethiopia ), Distilled 
water( Gondar hospital lab) ,Normal saline(Ethiopia pharmaceutical factory, Ethiopia), 
chloroform(ATCO, india) , Giemsa stain 10% solution (ScienceLab, USA), 
Microscope(OLYPUS cx21,Japan), N-hexane(ATCO, India), Ethyl acetate solution(ATCO, 
india)  , Mayer reagent (Avishkar Lab Tech Chemicals, India), Wagner‘s Reagent(BDH Ltd, UK 
), sulfuric acid (Supertek, India)  , Glacial acetic acid (Lobe chemi, India), microscope 
immersion oil (Neolab life  science co,  India),    ferric chloride (Fisher Scientific Co, USA), lead 
acetate (BDH Ltd, UK), Ammonium solution (Techno. Pharm. Chem., India),  Hydrochloric acid 
(Supertek Chemicals, India) ,Disposable  glove,  Hemotocapillary tube(Drummond scientific, 
USA) , Centrifuge, Desiccators, vials, rectal thermometer(TM01, Contronic manufacturing), 
Sensitive balance, separatory funnel, beaker , Microscopes slides(Westmed proxiGmGH CoKG, 
Germany), Erlenmeyer flasks, ball miller (FW100, China), in  hot air oven (YCO.IN010, 
INDIA) ,measuring cylinder, cotton gauze ,Watt man paper((EXACL,India0),Oral gavages , 
insulin with needles(Hindustan syringes and medical device PLC, India) and scissors. All 
chemicals and reagents were analytically graded and were procured from certified supplier. 
3.1.2. Collection and identification of plant material 
The fresh leaves of S. abyssinica were collected   in January, 2017   in the adjacent rural kebeles 
(Teda) of Gondar town, Ethiopia, which is 728 km far from Addis Ababa. The plant was selected 
based on the indigenous knowledge of the local traditional healers. It was identified by a botanist 
(Abiyu Enyew) and a voucher specimen of this plant is deposited in University of Gondar with 
voucher no MZoo1. 
3.1.3. Experimental animals 
The healthy young male albino mice (of age 6–8 weeks and weight of rages from 24-30 g were 
obtained from the University of Gondar. They were also be maintained under standard air 
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conditioned with at room temperature  and 50-70% relative humidity at half day light and  dark 
cycle. They were fed standard diet, and water ad libitum.  They were housed in a standard 
plasticcages . Animals were acclimatized for one week to the experimental environment. All the 
experiments were performed in accordance with the internationally laboratory animal use and 
care guideline(52). 
3.1.4. Parasite 
The rodent malaria parasite, Chloroquine- sensitive Plasmodium berghei NK 65, was obtained 
from Ethiopian Public Health Institute Addis Ababa, Ethiopia. The parasite was maintained alive 
by intraperitoneal passage in mice on weekly bases from infected donor blood to health mice by 
preparing 0.2ml infected blood via diluting with 0.9% normal saline solution treated by 0.5% 
trisodium citrate as an anticoagulant, until it would be reached to 10
8
 infected RBCs per ml. 
Then it was transferred by injecting 0.2ml of diluted infected blood (52).  
3.2. Methods 
3.2.1. Extraction of crude plant material 
First, fresh leaves were washed with distilled water to remove dust and debris, dried with air at 
normal temperature in the laboratory room for 2 weeks.  Then, the dried specimens were crushed 
into coarse powder using ball miller. After weighing by sensitive balance, the 1kg of specimen 
powder was macerated with 80% methanol for three days with occasional agitation and stirring.   
Next to that, it was filtrated with gauze and then with wattman paper No.1 with pore size 150 
mm diameters into Erlenmeyer flasks. Again the mark was remacerated twice in the same 
procedure . Then filtrates were combined and dried in hot air oven at a temperature of not 
exceeding 40
0
C. After the methanol was evaporated, the  crude extract  was farther  concentrated 
desiccators .Then the dried extract was transferred to vials and it was kept in desiccators a total 
of 168 gm (16.8 %(W/W))s was obtained. The portion of the crude extracts were used to 
evaluate the antimalarial activity in vivo model  and phytochemical screening and the remaining 
extract was subjected to n-hexan, chloroform, ethyl acetate and aqueous fractionation(53). 
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3.2.2. Solvent fractionation of S.abyssinica hydromethanolic extract 
Hydromethanolic crude extract of leaf S.abyssinic was subjected solvent fractionation with n-
hexane, chloroform and ethyl acetate solvents. A total of 140 gm of 80% methanolic crude extract 
of S.abyssinica was dissolved using separatory funnel in 350 ml distilled water, then fractionated 
by adding  n-hexane, chloroform and ethyl acetate solvents,  in increasing  order of their polarity. 
The dissolved hydromethanolic extract was partitioned with 3 ×350 ml n-hexan. Then, the filtrate 
was concentrated in hot air oven below 400C.The aqueous residue was further partitioned with 
3x350ml chloroform and filtrates were dried on hot air oven less than 40
0
C. The remaining 
aqueous again residue also further partitioned with 3x 350ml ethyl acetate which was  concentrated 
with hot air oven similar to the hexane and chloroform fraction. The remainig aqueous fraction 
was dried first in hot air oven, then with dedicator.  All fractions were kept in tightly closed 
containers in refrigerator at -20
0
C until used (42, 53).  
3.2.3.  Priminary phytochemical Screening 
The 80% methanol and the  solvent fractions(n-hexane, chloroform, ethyl acetate and aqueous s)  
of S. abyssinia leaves were screened for the presence of secondary metabolites Hence, screening 
tests for alkaloids, saponins, cardiac glycosides, flavonoids, terpenoids, steroids, phenols and 
tannins were performed using standard procedures (54)  as described in  annex 1. 
3.2.4. Grouping and dosing of animals  
There were 120 male mice were grouped randomly (after inoculation for chemosuppressive test 
and before inoculation for prophylactic test) into five groups of five mice each.  In both the 
chemosuppressive and chemoprophylactic models, group I mice were treated with10 ml/kg 4%   
tweene-80  ( used as negative control), the group II III and IV mice mice were treated with 100, 
200, and 400 mg/kg of crude extract, respectively. The rest group V was treated with the 
standard drug (chloroquine, 25 mg/kg, served as positive control), 
Previous toxicity studies made on hydromethanolic crude extract leaves of S.abyssinica  
demonstrated that  at 2000 mg/kg dose it was found safe and this  served as base for the 
determination  of the current antimalarial activity test doses  (100, 200 and400 mg/kg) of the 
extract . For all groups the route of administration was oral using oral gavage 
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3.3. In vivo antimalarial activity screening 
3.3.1. Inoculation of parasite 
Albino mice previously infected with Plasmodium berghei and having parasitemia level of 20-
30% were used as donor. The parasitaemia of the donor mice was first determined and 
parasitized erythrocytes were obtained by scarification using ethyl ether as anesthesia and diluted 
in physiological saline (0.9%). The dilution was made based on the parasitaemia of the donor 
mice and the RBC count of normal mice in such a way that 1 mL blood contains 5 × 10
7
 infected 
erythrocyte. The amount of 0.9% normal saline solution per ml added calculated as: 
                       VA-VB=VN 
Where: - VA: Volume of blood after addition of 0.9% normal saline  
              VB: Volume of blood before addition of 0.9% normal saline  
              VN: Volume of 0.9% normal saline added 
Each mouse was inoculated by intraperitoneal injection with a blood suspension (0.2 mL) 
containing 1 × 10
7
 parasitized erythrocytes (52).  
3.3.2. Chemo suppressive test 
This is the most widely used preliminary test, in which the efficacy of a compound is assessed 
by comparison of blood parasitemia and mouse survival time in treated and control. Treatment of 
infected mice was started after 3 h of infection on day 0 and continued daily for 4 days (i.e., from 
days 0–3). On the fifth day (day 4) blood samples were collected from tail snip of each mouse. 
Thin smears were prepared and stained with 10%Giemsa solution. Then, each stained slide was 
examined under the microscope with an oil immersion objective of 100× magnification power to 
evaluate the percent suppression of each extract with respect to the control groups (52). Average 
percent parasitaemia and suppression was calculated by using the following formula: 
 
                                             Number of parasitized red blood cells (RBC) × 100 
      % Parasitaemia=                   Total number of RBC count 
                                                 
        % Suppression= (% Parasitemia of negative control − % Parasitaemia of treated group)x100 
                                         % Parasitaemia of negative control 
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3.1.5. Evaluation of prophylactic activity (repository test) 
The hydromethanolic crude extract and one of among solvent fraction (the most active in chemo 
suppressive effect) were further tested using the residual infection procedure for prophylactic 
activity.  The vehicle, standard drugs and tested doses were administeredorally daily for four 
days (D0-D3).  On the five day (D4), all the mice were inoculated with 0.2 ml standard 
inoculums containing 1x 10
7
P. berghei infected erythrocytes as indicated in title3.3.2. After 72 h 
of infection (D7), thin blood smears were prepared from tail of each mouse  and examined 
microscopically for parasitaemia level, (52). 
3.1.6. Evaluation parameters  
A. Determination of parasitemia 
Thin blood smears were taken from tail snip of each mouse on the day 4 for 4-day suppressi ve 
test and on day7 for prophylactic test on microscopic slides. The slides were dried and fixed with 
absolute methanol. The slides were stained with 10% Giemsa at pH 7.2 for 10 minutes and then 
washed gently using distilled water and air dried at room temperature and examined under 
microscope with an oil immersion nosepiece of 100x magnification power. Percentage 
parasitemia were calculated as described in   title 3.3.2 
B. Determination of mean survival time 
The death of each mouse was observed and the number of days from the time of inoculation of 
the parasite up to death of each mouse in the treatment and control groups throughout the follow 
up period (30 days   for chemosupressive model and 21 days for prophylactic model) was 
recorded. The mean survival time (MST) for each group was then calculated using the following 
formula: 
           MST=Sum of survival time of all mice in a group (days) 
                     Total number of mice in that group 
 
C. Determination of packed cell volume (PCV) 
Packed cell volume (PCV) was measured to predict the effectiveness of the test fractions in 
preventing hemolysis resulting from increasing parasitemia associated with malaria. PCV is a 
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measure of the proportion of RBCs to plasma and measured before inoculating the parasite and 
after treatment of all groups of mice. It was measured before inoculating the parasite (day 0) and 
after treatment after 24 hour gap of the last dose in 4-day suppressive test  but  in case of 
prophylactic tests, the PCV were measured before infection ,D4 and D7.  
Blood were collected from tail of each mouse in heparinized microhaematocrit capillary tubes. 
The capillary tubes were filled with blood up to 75% of their height; sealed and placed in a 
microhematocrit centrifuge and centrifuged.  The blood was centrifuged at 12,000 revolutions 
per minute for 5 min. The tubes were then taken out of the centrifuge and PCV was determined 
using apparatus of the standard Microhematocrit Reader. 
 
          PCV=Volume of erythrocytes in a given volume of blood 
                         Total blood volume 
 
D. Determination of body weight 
The body weight of each mouse in all groups was measured before infection on day0 and on day 
4 in the four-day suppressive test. For prophylactic test, body weight was taken on day 4before 
inoculating parasite and on day 7; using a sensitive digital weighing balance. The mean 
bodyweight per group were calculated using the formula as indicated below:  
         Mean body weight =Total weight of mice in a group 
                                        Total number of mice in that group 
E. Measurement of body temperature 
To predict the effectiveness of the fractions on temperature, rectal temperature of each mouse in 
all groups were measured by a digital thermometer one hour before infection, and   then on day4 
day7 after infection for 4-day suppressive and prophylactic tests respectively.  
 
3.4. Quality control 
The reliability of the results of the research was maintained by using standard analytical grade 
reagents, more accurate measuring devices, accurate extracting procedure and performing tests 
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in triplicate (negative control, positive control groups and experimental group) with 
randomization and blind techniques.  
3.5. Ethical consideration 
The experiment protocols were requested to and approved by School of Pharmacy, College of 
Medicine and Health Sciences, University of Gondar. The experiment was performed according 
to the animal care and welfare guidelines (54). 
3.6. Statistical analysis 
Data were analyzed using Windows   SPSS 20 version software. One-way analysis of variance 
(ANOVA) followed by Tukey‘s post-hoc test was used to determine statistical significance for 
comparison of body weight, parasitemia percentage suppression, packed cell volume , rectal 
temperature and survival time among groups. The Student‘s independent t-test was applied to 
compare the PCV, rectal temperature differences, and body weight variations within a group 
taking the same dose extracts before and after the treatment at D0 and D4 for chomosupressive 
test and D4 and D7 for chemophylactic test. Results of the study was expressed as a mean plus 
or minus standard error of mean (M ± SEM). The analysis was performed with 95% confidence 
interval and P-values less than 0.05 is considered statistically significant. 
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4. RESULTS 
4.1. Percentage Yield of Plant Extract and Solvent Fraction 
The percentage yield of the crude hydro methanolic extract was found 16.80%. While the percentage 
yield of successive solvent fractions  of methanolic crude extract using hexane, chloroform, ethyl 
acetate and aqueous were 11.43%, 9.14%, 7.43%, and 72.00%,  respectively. 
4.2. Preliminary Phytochemical Screening  
The preliminary phytochemical screening test of 80% methanolic crude extract and its solvent 
fractions of the leaf of S.abyssinica revealed   the presence or absence of secondary 
metabolites as it stated in table1.  
Table 1:  Phytochemical screening of the leaves of crude extracts and solvent fractions of 
S.abyssinica  
 
Phytochemical 
constituent 
Crude 
extract 
Hexane 
fraction 
Chloroform 
fraction 
Ethyl 
acetate 
fraction 
Aqueous 
fraction 
Phenols + + + + + 
Flavonoids + + + + + 
Glycosides - - - - - 
Alkaloids + + + + - 
Saponins: + + + + + 
Steroids - - - - - 
Tannins: + + + + + 
Terpinoid - - - - - 
Anthraquinones - - - - - 
 
          Key: (+) =present of phytochemical, (-) = absent of phytochemical during test  
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4.3. Antimalarial Activity Evaluation  
4.3.1. In vivo antimalarial activity of the hydromethanolic extract of the leaf of 
Stephania abyssinica on four days suppressive test 
A. Effects of crude extracts of the leaf of Stephania abyssinica on percentage of 
suppression of parasitemia and mean survival time 
After  four day suppressive test, the present study shown that the percentage suppression of 80% 
methanolic extract was 29.15%, 40% and 45.60% at 100mg/kg, 200mg/kg and 400mg/kg of the 
extract, respectively in  a dose dependent manner. All the doses of the 80% methanolic extracts 
revealed  statistically significant difference (P < 0.05) antimalarial activity when compared to the 
negative control as shown in the table 2. The extract treated groups showed statistically 
significant difference at the dose of 400mg/kg (p<0.001) and 200mg/kg (p<0.001) when 
compared with 100mg/kg.  In the same manner, the 80% methanolic extract treated groups at the 
dose of 400mg/kg (p<0.01) showed statistically significant difference when compared to 
200mg/kg dose treated group. The chloroquine treated group was completely free from the 
parasites on day four as shown in table 2. 
As regards to survival days, the extract treated group at the dose of 400mg/kg (p<0.001) showed 
a statistically significance difference when compared to negative control and extract treated 
group at the dose of 100mg/kg (p<0.01). However extract treated groups, at the dose of 
200mg/kg and100mg/kg did not show statistically significant difference as compared to the 
negative control.  Chloroquine treated mice showed statistically significant (p<0.001) survival 
time with respect to all the extract treated groups and the control group as shown in table 2. 
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Table 2: Effect of crude extract the leaf of S. abyssinica on parasitemia level, % suppression and 
mean survival time of P. berghei infected mice in four day suppressive. 
 
Treatments(mg/
kg, ml/kg) 
Parasitaemia level %suppression  MST(day) 
Vehicle 10 39.40+0.68 0.00 6.80+.83 
HME100 29.15 +0.66
 a3d3e3
 29.15 8.6+ .37
e2
 
HME200 24.35+0.19
 a3c3e2
 40.00 9.80+51 
HME400   21.43+0.77
 a3c3d2
  45.60 10.20+.68
a3c2
 
CQ 25  0.00+0.00
 a3c3d3e3
 100.00 30.0 +0.00 
a3c3d3e3
 
Values are expressed as Mean ± SEM; n = 5.Where a = as compared to negative control ( 4% Tween- 80 
as a vehicle) 10ml/kg  ; b = as compared positive control(chloroquine 25mg/kg; c= 100 mg/kg; 
d=200mg/kg;e=400mg/kg;  1 = P < 0.05; 2 = P < 0.01; 3 = P < 0.001;CQ=chloroquine , 
HME=hydrometanolic extract ,MST=mean survive time. 
 
B. Effect of crude extract of the leaf of S. abyssinica on packed cell volume and 
body weight     
At 400 mg/kg tested dose hydromethanolic extract showed significant (p<0.05) difference 
prevention of PCV reduction as compared to the negative control. But both 200 and 100mg/kg 
the extract revealed non statically significant prevention of PCV reduction as compared to 
negative control. There were no statically significant differences in protection of PCV reduction 
between Chloroquine treated group and all crude hydromethanolic extract treated groups. But, 
positive controls shown stasticaly significant (p<0.01) in protection of PCV reduction as 
compared to the negative control. When compared to PCV change between Do and D4 with in a 
group, there was no significant differences in both the crude hydromethanolic extract treated 
groups at 400 mg/kg and chloroquine treated groups. But, the rest groups showed statically 
significant PCV reduction as compared to before treatment as shown in table 3. 
In 4-day suppressive test, the 80% methanolic extract at all tested dose revealed statistically 
nonsignificant (p>0.05) prevention effects of weight loss as compared to negative control.   
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Positive controls revealed significant difference (p<.05) in body weight loss prevention effect 
when compared to negative control. When compared to weight change between day4 and day 0, 
the negative control (p<0.01), 100 mg/kg dose (p<0.01) and 200mg/kg (p<0.05) dose treated 
groups lost their weight with significant differences as compare to before treatment on D0. 
Whereas, both 400mg/kg dose extract and chloroquine treated group  did not reveal significant 
differencse weight in weight changes as shown in table 3. 
. 
 
Table 3: Effect of crude extract of the leaf of S. abyssinica on packed cell volume and body 
weight of infected mice in the 4 ay suppressive test 
 
Treatments
(mg/kg, 
ml/kg) 
Packed cell volume (%)  
 
Body weight(g)  
 
D0  D4  % change  D0  D4     %Change  
Vehicle 10 54.20+.73 47.8.0+.73 -11.81 β3 26.48+.40 
    24.37+.57 
      - 8.00 β2 
HME100 54.20+1.77 50.40+1.86  -7.01 
β2 27.06+.27    25.59+.40        - 5.43 
β2 
HME200 55.00+.84 52.20+1.20   -5.09 
β2 26.87+.88    25.87+.84       -  3.71 β1 
HME400 54.60+1.03 53.40+.81 a1   -2.2 26.95+.48     26.44+.57          -0.69 
CQ 25 54.40+.51 54.6.0+.68 a2   0.37 27.25+.78 27.56+1.11a1           1.14 
Values are expressed as Mean ± SEM; n = 5.Where a = as compared to negative control (4% tween- 80 as  
a vehicle) 10ml/kg ; β= compare to before treatment within a group ; 1 = P < 0.05; 2 = P < 0.01;3=p<.001 
CQ=chloroquine, HME=hydrometanolic extract ; D0, at day 0 and D4, at day 4.  
 
C. Effect of crude extract of the leaf of S. abyssinica on body temperature of 
infected animals in the 4 day suppressive test 
 
Both 200 mg/kg and 400mg/kg dose extract significantly (p<.01)  attenuated the reduction in 
body temperature compared to negative control but at dose of100mg/kg, there was no significant 
difference  in temperature change as compared to negative control. When compare to the other 
groups with positive control, chloroquine 25mg/kg dose prevented body temperature reduction 
significantly with compare to negative control(p<0.001),100mg/kg extract(0.01), but, there were 
no statistically significant with 200mg/kg,400mg/kg doses extract . Positive control shown a 
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statically significant dereferences in protection of body temperature reduction as compared to 
100mg/kg treated groups (p<0.01), and negative control (p<0.001). Both negative control and 
lowest dose hydro methanolic extract treated groups lose their weight at D4 with compare to 
day0 before treatment (p<0.01) within the group but the other groups did not reveal body 
temperature reduction as shown in table4. 
 
Table 4: Effect of crude hydromethanolicextract of the leaf of S. abyssinica on body temperature 
of infected animals in the 4 day suppressive test  
Treatments(m
g/kg, ml/kg) 
 
          Temperature (
0
c)  
 
D0 D4  %Change  
Vehicle 10 
37.06+.11 35.92+.21 -3.08 
β2
 
HME100 36.94+.15 36.32+.21 -1.68 
β2
 
HME200 37.18+.14 36.88+.07 
a2
  -0.81 
HME400 37.00+.16 36.86+.17 
a2
   -0.38 
CQ 25 36.98+.12 37.26+.09 
a3c2
    0.76  
Values are expressed as Mean ± SEM; n = 5.Where a = as compared to negative control (4% tween- 80 as 
avehicle) 10ml/kg ;b = as compared positive control (chloroquine 25mg/kg; c= 100 mg/kg; β= compare to 
before treatment within a group ; 1; = P < 0.05; 2 = P < 0.01; 3 = P < 0.001, CQ=chloroquine  
,HME=hydrometanolic extract ;  D0, at day 0 and D4, at day4. 
4.3.2. Invivo antimalarial activity of the solvent fractions of leaf of Stephanica 
abyssinica on four days suppressive test 
A. Effect of solvent fractions of the leaves of S. abyssinica on parasitemia, % 
suppression and mean survival time of P. berghei infected mice in four day 
suppressive 
The result of 4-day suppressive test indicated that the percentage suppression of n-hexane 
fraction on hexane fraction treated groups   revealed 26.01 %, 36% and 42.50 % at 100mg/kg, 
200mg/kg and 400mg/kg of the fractions respectively. Hexane fraction at dose of 400mg/kg 
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revealed significant percentage suppression with compared to 200mg/kg (p<0.05),100mg/kg  
(p<0.01) of hexane fractions. 
The percentage suppression of chloroform fractions, on chloroform fraction treated groups, was 
34.83%, 48.08% and 55.8 % at 100mg/kg 200mg/kg  and 400mg/kg dose of the fractions 
respectively. Chloroform fraction at dose of 400mg/kg/ day (p<0.001), 200mg/kg (p<0.01), 
revealed significant percentage suppression with compared to 100mg/kg of chloroform fractions.  
On ethyl acetate treated groups, the percentage suppression of ethyl acetate fraction was 29.35 
%, 38.82% and 51.44 % at 100mg/kg, 200mg/kg and 400mg/kg of the fractions respectively. At 
dose of 400mg/kg , ethyl acetate fraction shown significant percentage suppression as compared 
to  at dose of 200mg/kg(p<0.05),100mg/kg(p<0.001) ethyl acetate fraction, but there was no 
statically difference between 200mg,100mg/kg  of its fraction in percentage suppression. All 
hexane, chloroform and ethyl acetate fractions; shown high percentage suppression (p<0.001) 
statistically significantly difference compared to that of the negative control. Positive control at 
25mg/kg shown significant percentage suppression (p<0.001) with compared to all hexane, 
chloroform, ethyl acetate fractions. The mice treated with CQ were completely free from the 
parasites on day four as described in table 5. 
 
The mean survival time of hexane fraction  (9.4+.34 with p<0.01),chloroform (10.40+.60with 
0.001) and ethyl acetate (10.4+.81 with p<0.01)fraction treated groups   reveled significantly 
increasing survival time at 400mg/kg doses compared to negative control (6.60+.24). At dose of 
200mg/kg , both chloroform (9.60+.40)and ethyl acetate (9.40+.40)fraction treated groups    did 
have prolonged the survive time significantly(p<0.01) as compare to negative control but hexane 
fraction treated groups (8.20+.49) at that dose did not reveal significant prolonged survival time 
a as compare to negative control. At dose of 100mg/kg, all hexane fraction (7.80+.37), 
chloroform fraction (8.40+.51) and ethyl acetate fraction (8.20+.20) group‘s prolonged survival 
time non-significantly as compared to negative control. Positive controls prolonged mean 
survive time greater than 30 days which was high significant difference (p<0.001) as compared 
to other groups as shown in table 5. 
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Table 5 Effect of solvent fractions of the leaves of S. abyssinica on parasitemia, % suppression 
and mean survival time of P. berghei infected mice in four day suppressive. 
 
Treatments(mg/kg, 
ml/kg) 
Parasitaemia level 
 
%suppression  
 
MST(day) 
Vehicle 10 40.20+1.32 -    6.60+.24 
HF100 29.73+.67
 a3b3 e3
  26.01      7.80+.37 
b3
 
HF200 25.71+1.30
 a3b3 e1
   36.00      8.20+.49 
b3
 
HF400 23.33+.1.05
 a3b3 d1
  42.50       9.40+.34 
a2 b3
 
CF100 26.20+.86 
a3b3d2e3
   34.83      8.40+.51 
b3
 
CF200 20.50+.55
 a3b3c2
   48.08       9.60+.40 
a2 b3
 
CF400  17.75+1.18
 a3b3c3
   55.80       10.40+.60 
a3 b3
 
EAF100 28.40+.51
 a3b3 e3
   29.35       8.20++.20 b
3
e
1
 
EAF200 24.59+.51
 a3b3 e1
   38.82       9.40+.40 
a2 b3
 
EAF 400 19.52+1.37
 a3b3c3d1
   51.44      10.40+.81 
a3 b3c1 
CQ 25 0.00+0.00
 a3c3d3e3 
      100        30.00+.00 a
3
c
3
d
3
e
3
 
 
Values are expressed as Mean ± SEM; n = 5.Where a = as compared to negative control ( 4% tween- 80 as  a 
vehicle) 10ml/kg  ; b = as compared positive control(chloroquine 25mg/kg; c= 100 mg/kg; d=200mg/kg 
;e=400mg/kg;  1 = P < 0.05; 2 = P < 0.01; 3 = P < 0.001CQ=chloroquine ; HF=n-hexane fraction; CF=chloroform 
fraction ;EAF=ethyl acetate fraction. 
 
B. Effect of solvent fractions of the leaf of S. abyssinica on packed cell 
volume and body weight of infected mice in the 4 day suppressive test 
 The hexane fraction treatment group at400mg/kg dose level showed statically significant 
differences on prevention against PCV reduction (p< 0.05) as compared to negative control. The 
hexane fraction treated groups at dose of 200 and 100mg/kg did not   show PCV reduction 
significantly (p>0.05) differences as compared to negative control on D4.  
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Chloroform fraction treated groups   at dose of 400 mg/kg (p<0.01), and 200mg/kg mg/kg 
(p<0.05) shown significant difference protection against PCV reduction when compared to the 
negative control, even though, lowest dose treated groups did not reveal significant difference 
against PCV reduction as compared to the negative control treated groups. 
 
 Ethyl acetate fraction treated at dose of 400mg/kg (p<0.01), 200mg (p<0.05) and 
100mg/kg(p<0.05) revealed  statically significant protection   PCV reduction as compared to 
negative control ,however, the lowest  dose treated groups did not reveal significant difference 
against PCV reduction as compared to the negative control treated groups. 
when compared with  positive control , at dose of all of  hexane, chloroform and ethyl acetate 
fraction treated groups  did not reveal  statically significant  differences against PCV reduction 
effect , however  positive control revealed statically significant difference in  protection of   PCV 
with compare to negative control(p<0.01). 
 
When compared to PCV change between Do and D4 with in a group,  negative 
control(p<0.01),N-hexane fraction at  dose of 200mg/kg (p<0.05)and 100mg/kg(p<0.01), 
chloroform  fraction at  dose of 100mg/kg (p<0.01),and ethyl acetate fraction at 200mg/kg 
(p<0.05)and 100mg/kg(p<0.01)   on D4 treated groups  had significant  PCV reduction as 
compared to PCV level of the groups on D0(pretreated groups) 
 
 On D4, there were no statically significant differences in the PCV reduction of N-hexane 
fraction at dose of 400mg/kg, chloroform fraction at dose of 400mg/kg and 200mg/kg, ethyl 
acetate fraction at 400mg/kg, and chloroquine treated groups as compared to the PCV level in 
D0 of the same groups. Hence the PCV reduction protective effects of the fraction depend on the 
dose level. 
 
All dose levels of all fractions  treated groups did not reveal  statically significance in weight 
lose changes as compared to the negative control groups, however , there were non significant 
increment of in percentage of  weight changes as compared to negative control. Positive control 
treated groups reveled statically significant (p<0.05) difference protection from body weight lose 
as compared to the negative control. There were no statistical differences between positive 
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control and fractions treatment groups of D4 weight on weight loss protection, however the 
positive control revealed increased body weight positively as compared to the fraction. 
 
When compared to  weight changes between Do and D4 with in a group,  negative 
control(p<0.001), the hexane fraction at  dose of 200mg/kg (p<0.05)and 100mg/kg(p<0.01), 
chloroform  fraction at  dose of 100mg/kg (p<0.05) and ethyl acetate fraction at 
100mg/kg(p<0.01)  on D4 treated groups  revealed  statically significant  weight lose  as 
compared to measured weight of  the same groups on D0(pretreated groups). At D4 the rest 
groups:  the n- hexane fraction at 400mg/kg dose,  chloroform  fraction at  dose of 200mg/kg and 
400mg/kg , Ethyl acetate fraction at 200mg/kg and 400mg/kg  and chloroquine treatment groups  
did not reveal a stastical difference in body weight  change as compared to the weights of the 
same group at D0. 
 Therefore, the above indicated   different solvent fractions protected the weight lose in the dose 
dependant manner as the dose level increased as shown in table 6 
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Table 6: Effect of solvent fractions of the leaf of S. abyssinica  on packed cell volume and 
body weight   of infected mice in the 4 day suppressive test. 
 
Treatments 
(mg/kg, 
ml/k
g 
     Packed cell volume (%)  
 
     Body weight(g)  
 
D0 D4 % change   D0 D4 % change 
Vehicle 10 55.00+1.58 48.20+2.25 -12.36
β2
 27.06 +.59 24.96+.57 -7.62
β3
 
 
HF100 55.80+.86 51.40+.81 -7.89
 β2
 27.12+.56 25.41+.51 -6.29
β2
 
HF200 55.00+.63 52.20+1.00 -5.09
β1
 26.87+.70 25.90+.51 -3.61
 β1
 
HF400 55.40+.510 53.80+.58
 a1
 -2.89 26.90+.75 26.16+.66 -2.72 
CF100 54.80+.37 51.40+.68 -6.20
β2
 27.62+.84 26.28+.81 -4.84 
β1
 
CF200 54.20+.37 53.20+.49
 a1
 -1.85 27.13+.84 26.39+.48 -2.73 
CF400 55.80+.93 55.00+.45
 a2
 -1.43 27.16+.47 26.84+33 -1.16 
EAF100 54.40+.81 50.80+1.39 -6. 3
β 2
 26.87+.31 25.52+.45 -5.02
β2
 
EAF200 54.60+.93 53.40+.89 -2.93
β1
 27.48+.81 26.44+.48 -2.93 
EAF 400 55.80+ 54.80+.58
 a2
 -1.79 26.93+.68 26.55+.80 -1.41 
CQ 25 55.20+1.02 55.40+1.25
 a2
 0.36  27.26+.54 28.87+.61 
a1
 
2.23 
 
Values are expressed as Mean ± SEM; n = 5.Where a = as compared to negative control (4%  Tween- 80 as a 
vehicle) 10ml/kg, β= as compared with before treatment within the group,1 = P < 0.05; 2 = P < 0.01; 3 = P < 
0.001 CQ=chloroquine; HF=n-hexane fraction; CF=chloroform fraction; EAF=ethyl acetate fraction; D0, at day 
0; and D4, at day 4.  
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B. Effect of solvent fractions of the leaf S. abyssiniaon body temperature of 
infected animals in the 4 day suppressive test  
The effect of   all solvent fractions fraction at 400mg/kg dose shown statically significant 
(p<0.05) activity on prevention against body temperature reduction as compared to negative 
control.In all fractions at tested doses of 100 and 200 mg/kg did not show statically significant 
difference effect on protection of body temperature reduction as compared to the negative 
control. Hexane fraction at 400mg/kg dose revealed statically significant (p<0.05) preventive 
effect on body temperature reduction as compare to hexane fraction at 100mg/kg dose. But the 
rest; chloroform and ethylacetate treated groups did not reveal   statically significant difference 
in body temperatures change as compared to different dose treatment groups of the same solvent 
fractions. The chloroquine treatment groups showed statically significant difference in the 
protection of temperature reduction as compared to 100mg/kg dose treatment groups of all 
fractions. 
 
 When compared the temperature change of the same group at D0and D4, both negative control 
(p<0.01) and all 100mg/kg (p<0.01), and 200 mg/kg(p<0.05)  solvent fractions tested groups 
shown body temperature reduction at D4 with compare to D0 before treatment  but the other all 
400 mg/kg solvent faction dose tested   groups  and positive controls did not reveal  significant 
body temperature reduction  as compared to measured body temperature  at Do   before 
treatment as described in table 7. 
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Table 7: Effect of solvent fractions of the leaf S. abyssiniaon body temperature of infected 
animals in the 4 day suppressive test  
Treatments(
mg/kg
, 
ml/kg 
Temperature (
0
c) 
 
D0 D4 % change 
Vehicle 10 
37.00+.06  35.86+19   -3.08 
β2
 
HF100 36.96+.07  35.90+.27
b3e1
    -2.87 
β2
 
HF200 36.84+.10  36.50+.13     -0.92 
β1
 
HF400    36.94+.14  36.74+.13
a1c1
        -0.54 
 CF100    36.86+.18 36.12+.06
b3
        -2.22 
β2
 
CF200    36.96+.14     36.68+13   -0.76
 β1
 
CF400 36.86+.17 36.78+19
a1
    -0.22  
EAF100 36.90+.12 36.02+.14
b3
     -2.38 
β2
 
 EAF200 36.94+.14 36.64+.14      -0.81 
β1
 
 EAF 400  36.92+.19    36.74+.19 
a1
        -0.49 
 CQ 25 37.20+.15     37.26+.09
a3c3
         0.16 
             Values are expressed as Mean ± SEM; n = 5.Where a = as compared to negative control ( 4% tween- 80 
as  a vehicle) 10ml/kg  ; b = as compared positive control(chloroquine 25mg/kg; c= 100 mg/kg;  β=  as 
compared with before treatment within the group ,1 = P < 0.05; 2 = P < 0.01; 3 = P < 0.001 
CQ=chloroquine ; HF=n-hexane fraction; CF=chloroform fraction ;EAF=ethyl acetate fraction;. D0, at 
day 0 ; and D4, at day 4.  
 
 
 
35 
 
4.3.3. Prophylactic Effect of hydromethonolic extract and chloroform fraction of leaf 
of S.abyssinica 
A. Effect of crude extract and cloroform fraction of the leaves of S. abyssinia on 
parasitemia, % suppression and mean survival time of P. berghei infected 
mice in prophylactic tests 
In a prophylactic test, effect of hydromethanolic crude extract treated groups  showed statistically 
significant difference on the percentage parasite suppression at a dose of 400mg/kg(p<0.001), 200mg/kg 
(p<0.001), and 100mg/kg (p<0.001) when compared to negative control. The extract treated group at the 
dose of 100mg/kg and 200mg/kg did not showed statistically significant difference parasite suppression 
as compared to each other. In the same manner, the extracted treated group at the dose of 200mg/kg and 
400mg/kg did not showed statistically significant difference parasite suppression as compared to each 
other. However, the extract treated group at the dose of 400mg/kg (P<0.001) showed statistically 
significant difference when compared to the extract treated group at the dose of 100mg/kg as shown in 
table 8.  
 
The percentage parasite suppression of chloroform fractions on prophylactic test, revealed statistically 
significant difference at the dose of 100mg/kg (P<0.001), 200mg/kg(P<0.001), and 400mg/kg(P<0.001) 
when compared to the negative control as it did by the 80% methanolic crude extract treated groups. The 
chloroform fraction treated groups at the dose of 200mg/kg (P<0.05) and 400mg/kg (P<0.001) revealed 
statistically significant difference when compared to 100mg/kg treated group. The chloroform fraction 
treated group at the dose of 200mg/kg and 400mg/kg did not revealed statistically significant difference 
when compared to with each other. Both, the 80% methanolic crude extract and chloroform fraction 
treated groups at all dose revealed statistically significant difference when compared to chloroquine 
treated group(P<0.001) as shown in table 8.  
The effect of  both 80% methanolic crude extract and chloroform fraction on mean survival time on 
prophylactic test, revealed statistically significant difference in the prolongation of mean survival time at 
the dose of 400mg/kg (P<0.01) as compared to negative control. The 80% methanolic crude extract and 
chloroform fraction at the dose of 100mg/kg and 200mg/kg did not revealed statistically significance 
difference in the prolongation of mean survival time when compared to negative control. While both 80% 
methanolic crude extract and chloroform treated groups at all doses revealed statistically significant 
difference in the prolongation of mean survival time when compared to chloroquine treated groups 
(P<0.001) as shown in table 8. 
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At dose of 400mg/kg, both the crude extract(9.60+.51 day)  and chloroform fraction(9.40+.51)  
prolonged the survival time significantly(p<0.01) as compared to negative control  and 
chloroquine treated groups survived more than 21days as shown in table 8. 
 
Table 8: Effect of crude extract and cloroform fraction of the leaves of S. abyssiniaon 
parasitemia, % suppression and mean survival time of P. berghei infected mice in 
prophylactic tests 
Treatments(m
g/kg, ml/kg) 
Parasitaemia 
level 
 
% suppression  
 
MST(day) 
Vehicle 10 22.03+.87 0 6.80+.37 
HME100 14.10+1.51
 a3b3e2
 35.91 7.60+.51
b3
 
HME200 11.49+.97
 a3b3
 47.77 8.60+51
b3
 
HME400 10.03+1.41
 a3b3c2
 54.41 9.60+.51
a2b3
 
CF100 13.67+1.51
a3b3d1c3
 37.86 8.40+.40
b3
 
CF200 10.55+.98
 a3b3c1
 50.77 8.80+.20
b3
 
CF400          9.33+.92
 a3b3c3
 57.59 9.40+.51
a2b3
 
CQ 25 3       0 .76+.10
 a3c3d3e3
 96.55 >21.00
a3c3d3e3
 
    
Values are expressed as Mean ± SEM; n = 5.Where a = as compared to negative control (4% twin- 80) 10ml/kg; 
b = as compared positive control (chloroquine 25mg/kg; c= 100 mg/kg; d=200mg/kg; e=400mg/kg; 1 = P < 
0.05; 2 = P < 0.01; 3 = P < 0.001. CQ=chloroquine , HME=hydrometanolic extract ; CF=chloroform fraction  , 
MST=mean survival time 
B. Effects on Packed cell volume and body weight   of infected mice treated with 
crude extract and chloroform fraction leaves of S. abyssinica in prophylactic 
tests 
 As compared to the PCV level on D7,the chloroform fraction at 400mg/kg  and positive controls 
revealed significant prevention  activity against  PCV reduction (p<0.05) as compared to 
negative control. All crude extract at dose of 100,200, and 400mg/kg did not reveal significant 
protection of PCV reduction (p>0.05) as compared to negative control. The there were 
nonstatically significant difference  effect on  PCV level among both crude hydromethanolic and 
chloroform fractions as compared  to based on  respective different dose levels. There was no 
significant difference between among crude hydromethanolic and chloroform fraction at 400,200 
and100mg/kg tested dose as compared to the positive control as described in table 9. 
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When compared PCV differences between D4and D7,  negative control(p<0.001),crude extract 
at  200 mg/kg(p<0.05),and100mg/kg(p<0.01),  and chloroform  at 200mg/kg (0.05)and100 
mg/kg (p<0.01)dose treated groups  revealed significant PCV reduction on  D7as compared to 
the PCV level on D4 within the same group. Where  both crude hydromrthanolic extract and 
chloroform fractions at 400 mg/kg and positive control groups did not reveal significant PCV 
reduction  on D7 as compared to the  PCV level on D4 as shown in the table 9. 
 
 Both crude hydromethanolic extract and chloroform fractions treated groups at all dose levels 
did not reveal statically significance in weight changes as compared to the negative control 
groups at D7, however, there were non significant increment of in percentage of  weight changes 
as compared to negative control. Positive control treated groups reveled statically significant 
(p<0.05) difference body weight change as compared to the negative control. There were no 
statistical differences between positive control and crude hydromethanolic extact and chloroform 
fractions treatment groups of body weight change, however the positive control revealed 
increased body weight positively as compared to both the fraction and the fraction. 
 
When compared to  weight changes between D4 and D7 with in a group,  negative 
control(p<0.01), the crude hydromethanolic extract at  dose of 200mg/kg (p<0.05)and 
100mg/kg(p<0.01),  and chloroform  fraction at  dose of 100mg/kg (p<0.01) treated groups at D7 
revealed  statically significant difference in weight lose   as compared to measured weight of  the 
same groups on D4(pretreated groups). The crude hydromethanolic extract treated groups at 
400mg/kg dose, chloroform fraction treated groups at dose of 200mg/kg and 400mg/kg, did not 
reveal statically difference in body weight loss as compared to the weights of the same group at 
D7. The chloroquine treated groups at D7 revealed statically significant difference in weight gain 
as compared to measured weight of the same groups on D4 as shown in table 9. 
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Table 9: Effect of packed cell volume and body weight   of infected mice treated with crude 
extract and chloroform fraction leaves of S. abyssinica in prophylactic tests. 
Treatments(
mg/kg, ml/kg) 
Packed cell volume (%) 
 
Body weight(g)  
D4 D7 % change D4 D7  %Change  
 Vehicle 10 55.40+1.25 49.80+1.16 -10.11
β3
 26.41+.72 24.63+.55 -6.70
 β2
 
 CQ 25      55.40+.51   55.20+.80
 a1
   -0.36  26.78+.82 27.33+.78
 a1
  2.06
 β
 
1
 
HME100 54.20+1.72 50.60+1.5 -7.19
β2
 26.90+.37 25.76+.38 -4.25
 β2
 
HME200 54.80+.66 52.40+1.24        -4.75
β1
 26.85+.55 26.14+.35 -2.66
 β1
 
HME400 54.60+1.03 53.40+1.00 -2.20  26.93+.49 26.57+.55 -0.63 
 CF100 55.20+.86 52.00+1.10 -5.80
 β2
 26.85+.43 26.2+.43 -3.10 
β2
 
CF200 54.80+.66 52.60+.93 -4.01
β1
 26.80+.61 26.18+.39 -2.31 
CF400 56.00+.71 55.20+.58
a 1
 -1.43 26.86+.38 26.77+.92 -0.58 
Values are expressed as Mean ± SEM; n = 5.Where a = as compared to negative control ( 4% tween- 80 as  
avehicle) 10ml/kg ; b = as compared positive control(chloroquine 25mg/kg ; β=as compare to before treatment 
within the group;  1 = P < 0.05; 2 = P < 0.01; 3 = P < 0.00 ;CQ=chloroquine ,HME=hydrometanolic extract ; 
CF=chloroform fraction .D4, at day 4 and D7, at day 7. 
 
C. Effect body temperature of infected animals treated with crude and solvent 
fraction of the leaf S. abyssinica in the prophylactic tests. 
 Both hydromethanolic crude extract and chloroform fraction at dose of 400mg/kg reveled   
statically  significant(p<0.05 )protective effect from  body temperature reduction as compared to 
body temperature of negative control,  however, at 100mg/kg and 200 mg/kg doses, both extract 
and Chloroform fraction  shown stastical  non- significant(p>0.05) protective effect as compared 
to the negative control. When compared to chloroquine treatment groups, both extract and 
chloroform fractions at 200mg,400mg/kg shown comparable protective effects from rectal 
temperature reduction ,but at 100mg/kg dose, chloroquine treatment shown significant difference 
(p<0.05). The positive control produced preventive activity from temperature reduction statically 
significant (P<0.01) difference when compared the negative control as shown in table10. 
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When compared to the body temperature difference between D4 (pretreatment) and D7 (after 
treatment, all negative control, crude hydromethanolic and chloroform fraction treated groups at 
200 and 100 mg/kg at D7 shown statically significant (p<0.05) body temperature reduction as 
compared to the body temperature on D4 before treatment. whereas   both crude extract  and 
chloroform fraction 400mg/kg   dose treated groups at D7 did not reveal significant temperature 
reduction as compared to body temperature  at day 4  and also the chloroquine treated groups did 
not produce statically significant body temperature increment as compared to the body 
temperature measured on D4 before treatment as shown in table10. 
 
Table 10:  Effect body temperature of infected animals treated with crude and solvent 
fraction of the leaf S. abyssinica in the prophylactic tests. 
 
Treatments(mg
/kg, ml/kg) 
Temperature (
0
c)  
D4 D7 %Change  
Vehicle 10 37.00+.15 36.48+.09 -2.27β1 
HME100 36.96+.17 36.56+.16
 b1
 -1.08
 β1
 
HME200 37.06+.09 36.80+.15 -0.81
β1
 
HME400 37.00+.16 36.82+.24
 a1
 -0.49 
CF100 36.88+.15 36.50+.14
 b1
 -1.03 
β1
 
CF200 36.96+.10 36.74+.14 -0.60 
β1
 
CF400 36.94+.15 36.82+.16
 a1
 -0.33 
CQ 25 37.02+.13 37.060+.18
a2 c
 +0.11 
Values are expressed as Mean ± SEM; n = 5.Where a = as compared to negative control ( 4% tween- 80 as  a 
vehicle) 10ml/kg  ; b = as compared positive control(chloroquine 25mg/kg; c= 100 mg/kg; β as compare to 
before treatment within groups;  1 = P < 0.05; 2 = P < 0.01;;CQ=chloroquine , HME=hydrometanolic extract ; 
CF=chloroform fraction .D3, at day 3 and D7, at day 7. 
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5. DISCUSSION  
The spread and occurrence of resistant malaria to the front line antimalarial drugs (including 
artemisinin) (1), toxicity of conventional antimalaria drugs ,absent of vaccine  and  the 
appeareance of insecticide resistant mosquitos are  the major challenges that overwhelm all 
recent gains in malaria control and has major implications for public health(9,12, 17). Hence, the 
scientific community is now underway to solve this problem by searching for new, safe, 
affordable and effective antimalarial agents from medicinal plants and other sources (56, 57). 
This study was conducted using in-vivo model in which the both crude hydromethanolic and 
fractions were tested against P. berghei infected mice. The in-vivo model was employed because 
it takes into account prodrug effect and possible involvement of immune system in eradication of 
infection (52, 58). 
 
Rodent models have been validated through the identification of several conventional 
antimalarials, for example chloroquine, halofantrine, mefloquine and more recently artemisinin 
derivatives (52). The common malaria parasite, chloroquine sensitive parasite, the P.berghie, is 
with proven use in the prediction of treatment outcomes and remains a standard part of the drug 
discovery pathway, hence, is the appropriate parasite for this study (52, 59). 
For antimalarial drug screening, the 4-day suppressive test is the standard test commonly used P. 
berghei infected mice are used for better prediction of antimalarial efficacy of drugs for human 
use in many studies in search of antimalarial drugs (52, 58). 
On preliminary phytochemical screening of hydromethanolic extract and  n-hexane, chloroform, 
ethyl acetate and aqueous solvent fractions  leaf of S. abyssinica  revealed   that alkaloids(absent 
in aqueous),  flavonoids , tannins, phenol  and  saponins  constituets were present  in both hydro 
methanolic crude extract as well as all solvent fractions. These phythochemicals have been well-
known for different pharmacological activities including antimalarial effects. Some alkaloids 
such as, quinine prevent polymerization of heme in haemozoin in the digestive vacuole. Phenolic 
compounds(flavonoids ,phenols and  tannins,) act as antioxidant or free radical scavenger to 
prevent/reduce oxidative stress induced by the parasite  Antioxidants can inhibit also heme 
polymerization and the unpolymerised heme is very toxic for the parasite  compounds detected 
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in the leaf of Stephania abyssinica for their antioxidant.  The sapponincs affect the cell 
membrane of the parasites.  Hence, these secondary metabolatites might be responsible for 
antimalarial activitie of the leaf Stephania abyssinica against Plasmodium berghei infection in 
mice (58, 59,60). 
 
Four-day suppressive test assesses the potential schizontocidal activity of hydromethanolic 
extracts and solvent fractions in early infection whereby the primary attack due to malaria can be 
prevented or mitigated (52). The hydromethanolic extract, hexane, chloroform and ethylacetate 
fractions at dose of 400mg/kg showed the maximum chemosupressive activities( 54.41%, 
42.50%, 55.80% and 51.44% respectively )on parasitemia level .This might be due to the 
presence of good concentrations of active compounds in higher dose. 
Chemoprophylaxitic test is one of other secondary antimalaria screening tests in rodent malaria 
(52). The chemoprophylactic activity of the crude extract and chloroform fractions were 
evaluated using the residual infection procedure. The crude hydromethanolic extract (54.41%), 
and chloroform fraction (57.59%) suppressions also showed chemoprophylactic activity against 
Plasmodium berghei infection in mice at 400mg/kg dose. This might be due to delay of 
metabolic clearance and tissue sequestration and redistribution of active photochemicals, which 
are responsible for parasite suppression, present in both extract and fraction when administered 
to the mice.  It also might be due to the phytochemicals preventive effect of the parasites 
adherence, cellular division on and/ or in the surface of erythrocytes or due to 
immunomodulating effect in mice (37, 38). 
 
Hence, hydromethanolic and all fractions can be considered to be active in their schizontocidal 
activity against malaria.  This finding supports the traditional use of the leaf of S.abyssinica and 
invitro antimalaria activity results for malaria treatment by the peoples of eastern Africa (36, 42, 
50). Since a compound is considered as active when percent, parasitemia inhibition is greater or 
equal to 30% (52) which is in agreement with this study.  
 
The antimalarial activity of  might be due to the presence of active secondary metabolites present 
in these extracts and fractions such as alkaloids, flavonoids ,tannins, phenol  and  saponins   and 
other untested constituents. These active secondary phytochemicals might inhibit or block folate 
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metabolism, protein synthesis, membrane transport system, haem polymerization, electron 
transportsystem, free radicals cavengers and other mechanism or path way of the parasite which 
might be similar to conventional antimalaria drugs and other unkown mechanisms (52,60, 61). 
These methabolites might act singly or in synergy with one another to produce the observed 
biological activities (60). 
As different evidences were acquired from different literatures, S.abyssinica showed an 
antiplasmodial activity (dichloromethane, IC50<3μg/ml, ethyl acetate IC50<5μg/ml and 
methanol fraction, IC50<9μg/ml)   against Plasmodium falciparum strains in invitero test (42, 
50). It also had antitumor (36), anti bacterial (36), antioxidant activity (48) in invitro   and 
antiinflamatory and analgesic in invivo test (49).It can be convenced from invivo 
chemosupresive effect because the leaf of the plant enriches in bisbenzylisoquinoline and 
hasubanane alkaloids (42).  
The positive control eliminated the parasite to non-detectable level and as a result led to survival 
time of more than 30days by inhibiting the aminoacide production and toxic intermidet product 
generation for parasite. The significantly lower parasitemia suppression by the extracts and 
solvent fractions as compared to the positive control could be due to low level of active 
compound(s) associated with the crude nature of the extract and fractions, non selectivity of the 
extract or slow absorption and low bioavailability of these extracts (59). 
 
The mean survival time is the second important parameter to test the antimalarial activity of 
plant extracts (52).  Both of the extracts and solvent fractions of S.abyssinica prolonged the 
survival time of mice which might be due to the suppression of parasitemia and reduced the 
overall pathologic effect of the parasite on the study mice (38, 62). The mean survival time of  
hydromethanolic extract and solvent fractions at 400mg/kg revealed in significant prolongation 
as compared to the negative control in both chemosupresive and chemophylactic mice models. 
However, other lower doses of both methanolic extract and solvent fractions did not reveal 
significant prolongation of means survival time as compared to negative control. It could be 
related to the presence of active secondary metabolites in sufficient concentration unlike that of 
the lower doses. This indicates that these doses suppressed P. berghei and thereby reduced 
anemia and the overall pathologic effect of the parasite on the test groups (61, 38,  62).  
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Packed cell volume (PCV) is one of   the third parameter that used to predict the effectiveness of 
the test extract and fractions in preventing hemolysis resulting from increasing parasitemia 
associated with malaria (10). Post infection of malaria, the rodents suffer from anaemia because 
of RBC destruction by The underlying cause of anemia includes; loss of infected erythrocytes 
through parasite maturation, destruction of uninfected red cells in the spleen and liver by 
macrophages activation and/or enhanced phagocytosis, reduced erythropoiesis and 
dyserythropoiesis ( 38, 59,61). 
 
At 400 mg/kg tested dose both hydromethanolic extract and fractions shown significant 
protection against PCV reduction in both models. But the lowest dose did not protect against 
PCV reduction due to plasmodium infection. This protection effect could be as a result of the 
significant parasite suppression effect induced by active constituents in the administered doses of 
crude extract and fractions at 400mg/kg were sufficient enough to prevent/delay RBC hemolysis 
that could be linked to the higher concentration active constituents in the administered dose 
(38,62). 
  
The protective effect of both crude hydromethanolic extracs and fractions against PCV reduction 
due to parasite might be due to destructive antiplasmodial effect of the extract and fractions 
against the parasitized red blood cell and the causative parasite, thereby sustaining the 
availability of the new red blood cells produced in the bone marrow (37, 62).  
 
The fourth parameter in the evaluation of antimalaria screening is the effects of the plant on 
malaria-induced weight lose. Anemia, body weight loss and body temperature reduction are the 
highmarks of malaria infected mice. Weight decrement has been associated with decreased food 
intake, disturbed metabolic function and hypoglycemia .So, an ideal antimalarial agents obtained 
from plants are expected to prevent body weight loss in infected mice due to the rise in 
parasitemia(37,63,64 ). 
 
It was observed that the crude hydromethanolic extract and n- hexane fraction at 400mg/kg dose,  
chloroform  and ethyl acetate fraction fractions at  dose of 200mg/kg and 400mg/kg protected 
the body weight lost in chemosepresive test. And the crude hydromethanolic extract treated 
group at 400mg/kg dose, chloroform fraction treated groups at dose of 200mg/kg and 400mg/kg 
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also revealed significant protective effect against body weight in chemoprophylactic test. These 
indicate that these doses suppressed P. berghei and thereby reduced anemia and the overall 
pathologic effect of the parasite on the test groups (38, 64, and 65).But the rest fraction and 
crude extract doses did not keep body from weight lost in all models which might be insufficient 
phytochemical concentration in lower doses. Therefore, the above indicated both crude and 
different solvent fractions protected the weight lose in the dose dependant manner as the dose 
level increased.  
 
The last parameter is temperature change evaluation. A decrease in the metabolic rate of infected 
mice occurred before death and was companied by a corresponding decrease in internal body 
temperature. This implies that infected mice body temperature drops as parasite level grow 
rapidly. This decrement in temperature has been associated with reduction in basal metabolic 
rate and impact of anemia on heat production and/or heat conservation (38, 65,66, ).   
 
 Both crude hydromethanolic and solvent fractions significantly attenuated the reduction in body 
temperature soundly at 400mg/kg comparable to chloroquin in both models. The lowest dose 
hydro methanolic extract and all fractions at 100mg/kg and 200 mg/kg fractions did not 
significant protect body temperature reduction. This might be due to availability of sufficient 
active phytochemicals in higher doses that attacked against Plasmodium berghei and others 
pathological abnormalities in mice due to infection (38, 62)  
 
A cording to  Deharo E  et al, in vivo antiplasmodial activity can be classified as moderate, good 
and very good if an extract displayed a percent parasite suppression equal to or greater than 50% 
at a dose of 500, 250 and 100mg/kg body weight per day, respectively (67). Based on this 
classification, both crude hydromethanolic and fractions leaf of S.abyssinica of had a moderate 
antiplasmodial activity against P. berghei infection in mice on both four-day suppression and 
prophylactic tests. The moderate antiplasmodial effect revealed by the  hydromethanolic extract  
and fractions with the longest survival time compared to negative control,preventive effect  of 
PCV reduction, weight lose and temperature reduction could be related with  the presence of 
active secondary metabolites in sufficient amount. 
. 
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6. CONCLUSION  
 
From this study, it can be concluded the leaf of S.abyssinica revealed moderate chemosupresive 
and moderate chemophylactic antimalarial activities against Plasmodium berghei infection in 
mice and uphold with the the invitro antimalaria test results and justified traditional claims made 
by the peoples of Keynia. Accordingly, with the essence of further studies this plant could serve 
as the potential source of new and novel antimalarial leads and/or drugs for the treatment and 
preventionof malaria. 
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7. RECOMMENDATION   
Based on the present finings it could be recommended as follow:  
 Isolation and identification of the active constituents of leaf of Stephania abyssinica 
should be done 
 The aqueous fraction evaluated in chemosupressive model, prophylactic and curative 
models 
 The hydromethanolic extract and solvent fractions should be further evaluated in curative 
test.. 
 Further studies shall be carried out to determine the mechanism of action(s) responsible 
for the antimalarial activities. 
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Annex 1: PREMINARY PHYTHOCHEMICAL SCREENING 
PROCEDURES 
Test for Alkaloids; Crude extract and each solvent fractions were  mixed with 2ml of 1% HCl 
and heated gently. Mayer‟s and Wagner‘s reagents were then added to the mixture. Turbidity of 
the resulting precipitate was taken as evidence for the presence of alkaloids. 
Test for Terpenoids; Five ml of extracts and fractions dissolved in distilled water were mixed 
in 2 ml of chloroform, and 3 ml concentrated sulfuric acid was carefully added to form a layer 
and then  observed a  reddish brown coloration of the interface  to detect the presence of 
terpenoid.  
Test for Steroids; About 2 ml of extract and  individual different fractions were  dissolved in 2 
ml of chloroform and 2 ml concentrated sulfuric acid was added in extract  and  individual 
different fractions. Then observation of a red color produced in the lower chloroform layer when, 
indicates presence of steroids 
Test for Flavonoids; Both extracts and fractions were dissolved in a mixture of 4%Tween. ssTo 
2 ml of the extracts and fractions solution, few drops of 2 % lead acetate solution was added. 
Then, it was observed whether it develops yellow or orange color, which indicates the presence 
of flavonoids  
Test for Tannin : About 2 ml of the extract  and 2 ml solvent fractions  were  was stirred with 2 
ml of distilled water and few drops of ferric chloride solution were added. The formation of 
green precipitates indicates for the presence of tannins 
Test for saponins    5 ml of extract and solvent fractions were shaken vigorously with 5 ml of 
distilled water for 15 minutes in a test tube. The formation of stable foam was taken as an 
indication of the presence of saponins.  
Test for phenols;   About 0.5gm of extract and solvent fractions were dissolved in 5ml of 
distilled water. Then few drops of 5% ferric chloride solution were added and observed for 
formation of deep blue or black color. 
Test for cardiac glycoside; Few drops of ferric chloride and concentrated sulfuric acid were 
added in solution of the extract and fraction individually in glacial acetic acid. The formation of 
reddish brown coloration at the junction of two layers and the bluish green color in the upper 
layer indicates the presence of glycosides 
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Test of anthraquinones: about 0.5 g of the extract and fractions were taken into a dry test 
tube and 5 mL of chloroform was added and shaken for 5 min. then, filtered and the filtrate 
shaken with equal volume of 10% ammonia solution. Observing for a pink violet or red color 
in the ammoniacal laye (lower layer) indicates the presence of this secondary metabolite. 
  
